Massimo Breccia
0000-0003-1163-6162
31 papers found
Refreshing results…
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Digital droplet PCR at the time of TKI discontinuation in chronic‐phase chronic myeloid leukemia patients is predictive of treatment‐free remission outcome
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life
Missing publications? Search for publications with a matching author name.